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, and a range of comparator agents against clinical isolates of gram-positive pathogens.
The antibacterial agents used in the study were obtained from the following sources: BAL0030543, BAL0030544, and BAL0030545, Basilea Pharmaceutica AG, Switzerland; daptomycin (lot no. 095703A), Cubist Pharmaceuticals, Inc., Lexington, MA; linezolid (lot no. 05003), Pfizer Ltd., Surrey, United Kingdom; moxifloxacin (lot no. BX01US1), Bayer plc, Berkshire, United Kingdom; vancomycin (lot no. 1671543B), Alpha Pharma, Devon, United Kingdom; minocycline (lot no. 014K1207) and trimethoprim (lot no. 68H140), Sigma Ltd., Dorset, United Kingdom. A total of 225 clinically significant gram-positive isolates from the collection held in the Department of Medical Microbiology, Southmead Hospital, Bristol, United Kingdom (1994 to 2008) were used (Table 1) . Heterovancomycin-resistant Staphylococcus aureus (hVISA) and vancomycin-resistant Staphylococcus aureus (VISA) strains were identified by population analysis profiling (12) . MICs were determined using the Clinical and Laboratory Standards Institute agar dilution method for staphylococcal and listerial strains (3), using Mueller-Hinton broth supplemented with 5% lysed horse blood for S. pneumoniae, Streptococcus mitis, and beta-hemolytic streptococci, and using Corynebacteria sp. Mueller-Hinton broth supplemented with 50 mg/liter calcium for daptomycin. S. aureus ATCC 29213 and S. pneumoniae ATCC 49619 were used as control strains. The percentage of susceptible strains using Clinical and Laboratory Standards Institute breakpoints was calculated (4) .
The antibacterial activities of BAL0030543, BAL0030544, BAL0030545, and the comparator drugs are shown in Table 1 . BAL0030543 and BAL0030544 had the lowest MIC 50 s (0.03 g/ml) of the four DHFR inhibitors tested against methicillin (meticillin)-sensitive S. aureus (MSSA) strains, and the maximum MIC for the BAL compounds was 0.25 g/ml (BAL0030544 and BAL0030545). As expected, the MSSA strains were susceptible mainly to the comparator agents. BAL0030543 had the lowest MIC 50 of the DHFR inhibitors to 0.5 g/ml against the VISA strains but lower against the hVISA strains, being in the range of 0.06 to 0.25 g/ml. The MIC 50 for all three BAL compounds was 0.06 g/ml against coagulase-negative staphylococci; the MIC 90 s ranged from 4 to 8 g/ml. In contrast, the trimethoprim MIC 90 was 32 g/ml. The BAL0030543, BAL0030544, and BAL0030545 MIC 50 values for beta-hemolytic streptococci (Lancefield groups A, B , C, and G) ranged from 0.015 to 0.06 g/ml, and no isolates had a MIC of Ͼ0.25 g/ml for the BAL compounds. These strains were also susceptible to the comparator agents tested, with the exception of minocycline against group B streptococci. The BAL compounds were markedly more potent against S. pneumoniae strains than trimethoprim. BAL0030543, BAL0030544, and BAL0030545 MIC 50 s for Corynebacteria spp. were 0.06, 0.12, and 0.12 g/ml, respectively, with the MIC 90 being 4 g/ml for all three drugs. This is significantly more potent than the trimethoprim MIC 50 /MIC 90 at 16/16 g/ml. All five DHFR inhibitors had excellent activity against Listeria monocytogenes, with MIC 50 s of Յ0.06 g/ml and MIC 90 s of Յ0.06 g/ml. BAL0030543, BAL0030544, and BAL0030545 had lower MIC 50 s of Յ0.03 g/ml against S. mitis than trimethoprim (MIC 50 , 4 g/ml).
Five MRSA and two MSSA strains were resistant to trimethoprim, but none had a MIC of Ͼ0.5 mg/liter to the BAL compounds. Six of the VISA strains were trimethoprim resistant, of which five strains had BAL MICs of Ͻ0.5 mg/liter. One VISA strain had a raised MIC to the BAL compounds (Ն8 mg/liter). Similarly, of the four hVISA strains that were trimethoprim resistant, all had BAL MICs of Ͻ0.5 mg/liter. Of the 15 coagulase-negative staphylococcus strains that were trimethoprim resistant, four strains had BAL MICs of Ͼ0.5 mg/ liter.
The present study confirms the in vitro potency of BAL0030543, BAL0030544, and BAL0030545 against S. aureus isolates. Previously, it has been shown that the MIC 50 s of all three compounds were 0.03 g/ml against MSSA strains, MRSA strains, and strains with reduced vancomycin susceptibility (5). Our data indicate that these compounds had MIC 50 s in the range of 0.015 to 0.25 g/ml, depending on the compound and the S. aureus resistance phenotype. All the MSSA, MRSA, and hVISA isolates had MICs of Յ0.25 g/ml. VISA strains had higher MIC 90 s than other S. aureus stains, which has been described before and is probably related to the higher trimethoprim MICs in this group in general. BAL0030543, BAL0030544, and BAL0030545 are about fourfold less active against trimethoprim-resistant S. aureus than susceptible strains (5). BAL0030543, BAL0030544, and BAL0030545 have been shown in time-kill experiments to produce a 3-log reduction in viable counts of most S. aureus isolates and are more bactericidal against S. aureus than minocycline, linezolid, or clindamycin (8) .
Our data extends the data available on the BAL DHFR inhibitors against beta-hemolytic streptococci, indicating that all three compounds are highly active against Lancefield group A, B, C, and G streptococci. The previously reported geometric mean MIC for Streptococcus pyogenes was 0.25 g/ml, fourfold higher than the MIC 50 s obtained for our strains (11) . Some Corynebacteria sp. isolates had MICs above 1 g/ml, while all three compounds had MICs of Յ0.25 g/ml against S. pneumoniae, Յ0.06 g/ml against L. monocytogenes, and Յ0.12 g/ml against S. mitis.
In conclusion, the improved in vitro potency of BAL0030543, BAL0030544, and BAL0030545 against grampositive bacterial organisms compared to that of other DHFR inhibitors and their activity against isolates resistant to other drug classes justify further assessment of their utility in the therapy of gram-positive bacterial infection. The ability of dihydrophthalazine antifolates to be administered orally and parentally is an additional therapeutic benefit.
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